Company intelligence / Profile preview

Aston Sci

Ownership: Private
Development stage: Phase 2

Overview

Aston Sci is a clinical-stage biopharmaceutical company developing innovative immunotherapies, particularly therapeutic cancer vaccines. The company has received US FDA approval to initiate a Phase 2 trial for its ovarian cancer vaccine AST‑201, as well as regulatory approval in Taiwan to begin a Phase 2 trial of AST‑301 targeting HER2-expressed gastric cancers. Other pipeline assets are in earlier stages targeting various oncology indications[5].

Therapeutic areas: Oncology
Modalities: Therapeutic vaccinesmRNA vaccinesDNA vaccinesSmall molecule drugsBiological products[3][5]
Industry: Biotech

Drug pipeline

7 assets

HER2 ICD vaccine

6 more assets in the full pipeline.

Request access →

Partnerships

EpiThany Inc. (USA) – strategic partnership established in the company's early years[1].No other major partnerships disclosed.

Beyond the preview

Go deeper on Aston Sci.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aston Sci.

Explore the full profile